LILLY ELI & CO shareholders Q3 2023

LILLY ELI & CO's ticker is LLY and the CUSIP is 532457108. A total of 2,904 filers reported holding LILLY ELI & CO in Q3 2023. The put-call ratio across all filers is 1.16 and the average weighting 0.8%.

LILLY ELI & CO shareholders Q3 2023
NameSharesValueWeighting ↓
NatWest Group plc 17,338$9,312,7604.85%
Raub Brock Capital Management LP 44,613$23,963,0844.76%
WINSLOW ASSET MANAGEMENT INC 37,905$20,3604.72%
Sustainable Insight Capital Management, LLC 8,957$4,811,0734.72%
Cypress Capital Group 60,024$32,240,7344.66%
South Street Advisors LLC 42,847$23,014,4094.62%
Tower View Wealth Management LLC 12,179$6,5424.60%
TSP Capital Management Group, LLC 21,900$11,763,1494.54%
Schear Investment Advisers, LLC 7,767$4,171,8894.50%
Trifecta Capital Advisors, LLC 25,785$13,849,9034.45%
Corundum Trust Company, INC 2,747$1,475,4964.41%
MORGENS WATERFALL VINTIADIS & CO INC 10,100$5,425,0134.39%
Argyle Capital Management Inc. 22,182$11,914,6184.36%
PEOPLES FINANCIAL SERVICES CORP. 17,145$9,209,0684.34%
Fi3 FINANCIAL ADVISORS, LLC 14,798$7,948,3274.28%
Aldebaran Capital, LLC 7,783$4,180,4834.26%
MOODY LYNN & LIEBERSON, LLC 90,709$48,722,5254.18%
Gunderson Capital Management Inc. 11,331$6,086,2204.14%
BAROMETER CAPITAL MANAGEMENT INC. 24,150$12,971,6904.09%
Sivik Global Healthcare LLC 15,000$8,0574.07%
About LILLY ELI & CO

Lilly Eli & Co is a pharmaceutical company that has been in operation for over 140 years. The company is known for its innovative research and development of drugs that have helped millions of people around the world. The company's mission is to make life better for people by discovering and developing new medicines that improve their health and well-being.

Lilly Eli & Co has a strong pipeline of drugs that are in various stages of development. The company is focused on developing drugs for cancer, diabetes, and Alzheimer's disease. The company's research and development efforts have resulted in the development of several blockbuster drugs, including Cialis, Humalog, and Prozac.

The company's leadership team is made up of experienced professionals who are committed to the company's mission. The CEO, David Ricks, has been with the company for over 20 years and has a deep understanding of the pharmaceutical industry. The company's board of directors is also made up of experienced professionals who bring a wealth of knowledge and expertise to the company.

Lilly Eli & Co is committed to sustainability and has implemented several initiatives to reduce its environmental impact. The company has set ambitious goals to reduce its greenhouse gas emissions, water usage, and waste generation.

In conclusion, Lilly Eli & Co is a pharmaceutical company that has a long history of developing innovative drugs that improve people's lives. The company's strong pipeline of drugs and experienced leadership team make it a promising investment opportunity for stock market investors.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists LILLY ELI & CO's shareholders in Q3 2023. To view LILLY ELI & CO's shareholder history, click here.